In an era of entrenched partisan division, the House of Commons found a rare area of agreement on Wednesday, as MPs from across the political spectrum rose to welcome the government’s confirmation that the life sciences sector plan had attracted £3 billion in investment a full year ahead of its target. The debate, held in Westminster Hall rather than the main chamber, was notable less for its content than for its tone: constructive, informed and, for long stretches, genuinely collegial.
The Minister for Science, opening the discussion, laid out the details of the investment milestone, emphasising the geographic spread of the funding and the number of jobs created. But it was the contributions from backbenchers on both sides that gave the debate its distinctive character. The Conservative MP for Cambridge South, a former university lecturer in molecular biology, described the investment as “a down payment on Britain’s scientific future” and urged the government to resist the temptation to treat the milestone as a destination rather than a waypoint.
“Three billion pounds is a remarkable achievement,” the MP said. “But the United States invests more than that in biomedical research every quarter. China is building laboratories at a pace that would make our Victorian railway engineers blush. If we are to compete, and we must compete, then we need not just a one-off injection but a sustained, predictable, cross-parliamentary commitment to science funding.”
The point was echoed by the SNP spokesperson for innovation, who noted that Scotland’s universities and research institutes had benefited significantly from the sector plan but warned that the funding settlement beyond 2028 remained uncertain. “Researchers plan in decades, not in spending review cycles,” the SNP MP argued. “A postdoctoral student starting a five-year project today needs to know that the funding will still be there when they finish. That requires a commitment that transcends any single government.”
The Labour backbenches were equally vocal in their support, though several MPs used the opportunity to press for greater attention to applied research and commercialisation. The member for Manchester Central, a former engineer, argued that Britain’s historical weakness lay not in discovery but in translation. “We win Nobel Prizes and then watch the companies built on those discoveries move to Boston or San Diego,” the MP said. “The sector plan addresses that, but only if we maintain the pressure. Only if we build the manufacturing capacity, the regulatory agility and the patient capital to see ideas through to market.”
